REDWOOD CITY, Calif.--(BUSINESS WIRE)--Jun. 4, 2013--
Codexis, Inc. (NASDAQ: CDXS), a developer of engineered enzymes for
pharmaceutical, biofuel and chemical production, today announced the
appointment of Scott Watson as Vice President of Sales and Marketing,
effective May 2013. Mr. Watson has more than 25 years of experience in
sales, marketing and business development, including in the
pharmaceutical and fine chemicals markets.
“Scott brings a strong track record of success to Codexis, along with a
wealth of knowledge and connections from his various roles in the
pharmaceutical and fine chemical industries,” said John Nicols,
President and CEO of Codexis. “We continue to expand our pharmaceutical
business through new collaborations with strategic partners, and this
hire will allow us to capitalize on the many opportunities within both
the pharmaceutical industry and other complex chemistry markets where
our tailored enzymes can provide significant benefits for our customers.”
“Codexis is the world leader in developing biocatalysts for the
pharmaceutical industry and I am very excited to be joining the team at
this time,” said Scott Watson. “The opportunities in the pharmaceutical
market continue to grow, and I look forward to helping Codexis further
expand its presence, in pharmaceutical and other complex chemistry
markets, during the coming years.”
Before joining Codexis, Mr. Watson served most recently as the Executive
Director of Sales and Marketing at AMPAC Fine Chemicals, a leading
manufacturer of custom small molecule active pharmaceutical ingredients.
From 2008 to 2009, Mr. Watson served as Vice President of Sales and
Marketing for Girindus, a diverse service company to the pharmaceutical
industry, where he was responsible for realigning the company’s sales
strategy. Prior to Girindus, Mr. Watson held sales positions of growing
responsibility with various companies, including Aptuit, DSM and Eastman
Mr. Watson is a former officer in the U.S. Navy and holds a B.S. in
Chemistry from the U.S. Naval Academy and an M.B.A. in Finance and
Marketing from George Mason University.
About Codexis, Inc.
Codexis, Inc. engineers enzymes for pharmaceutical, biofuel and chemical
production. Codexis’ proven technology enables scale-up and
implementation of biocatalytic solutions to meet customer needs for
rapid, cost-effective and sustainable process development – from
research to manufacturing. For more information, see www.codexis.com.
This press release contains forward-looking statements relating to the
expansion of Codexis’ pharmaceutical business, Codexis’ abilities to
capitalize on business opportunities in the pharmaceutical and other
markets and the benefits that Codexis’ enzymes can provide its
customers. You should not place undue reliance on these forward-looking
statements because they involve known and unknown risks, uncertainties
and other factors that are, in some cases, beyond Codexis’ control and
that could materially affect actual results. Factors that could
materially affect actual results include Codexis’ dependence on a
limited number of customers and a limited number of products in its
pharmaceutical business, Codexis’ abilities to develop and commercialize
new products for the pharmaceutical market, Codexis’ dependence on its
collaborators and the successful management of these relationships in
developing and commercializing new products, Codexis’ ability to deploy
its technology into market spaces adjacent to its pharmaceutical
business and Codexis’ customers receiving regulatory and market approval
of their pharmaceutical products.
Source: Codexis, Inc.
Paul Cox, 212-362-1200
Connor, +44 161 359 3255